Canopy Growth Reports Second Quarter Fiscal Year 2027 Financial Results; Net Revenue Growth of 22% Led by a 141% Increase in International Markets Cannabis

Canopy Growth reported a 22% increase in net revenue to $81.4M for Q2 FY2027, with cannabis segment revenue up 30%. International markets saw a 141% revenue growth, driven by Europe. The company expects to reach positive adjusted EBITDA in FY2027, with ongoing cost savings and international expansion.

Original reporting
Published Nov 6, 2026, 12:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Canopy Growth Reports Second Quarter Fiscal Year 2027 Financial Results; Net Revenue Growth of 22% Led by a 141% Increase in International Markets Cannabis — source image
Decision brief

The 30-second read

$CGCBearishMed
01

Why it matters

The earnings release provides fresh data on revenue growth, margin trends, and progress toward profitability, which can affect investor positioning in the cannabis sector.

02

Market read

First‑time earnings numbers for a major cannabis player, indicating strong international growth and a path to positive EBITDA, likely to move the stock and sector.

03

What to watch

The impact of reduced Canadian veterans' reimbursement and inventory step‑up charges could limit near‑term profitability.

Relevance 7/10Novelty 8/10Timing: today, following the 10:00 AM ET webcast release

Background

Canopy Growth is a leading Canadian cannabis producer listed on both TSX (WEED) and Nasdaq (CGC). The company is pursuing international expansion, particularly in Europe and the UK.

Company-level read

Ticker impact

$CGCBearishHigh confidence
Context

Canopy Growth reported Q2 FY2027 results with 22% revenue growth and progress toward positive adjusted EBITDA.

Expected impact

potential upside as market prices in strong international revenue growth and path to profitability

Evidence & confidence

The press release provides first‑time earnings numbers showing double‑digit revenue growth and an improving adjusted EBITDA loss, which are new material facts for investors.

Market effects

Highlights growth in the cannabis sector, especially international medical markets.

Boosts sentiment for Canadian and European cannabis stocks.

Signals expanding demand for medical cannabis globally, may influence related biotech and consumer discretionary themes.

Counterpoint

Despite revenue growth, the company still reports a net loss and margin compression, suggesting caution.

Key entities

  • Canopy Growth Corporation

    Cannabis producer reporting Q2 FY2027 results.

  • MTL Cannabis Corp.

    Acquired entity contributing to revenue growth.

Related articles

$CGCMed

Canopy Growth (CGC) Q2 2027 Earnings Call Transcript

Canopy Growth (CGC) reported Q2 2027 revenue of $81.4M, up 22% YoY, driven by 30% cannabis segment growth. Medical cannabis and international markets showed momentum, while Storz & Bickel revenue fell 44% YoY to $50.1M. The company expects improved yields and EU GMP certifications to boost growth and margins. Adjusted EBITDA loss narrowed to $2.9M, with a target of profitability in H2 2027.

$CGCMedAI 8/10

Canopy Growth Corporation Q2 2027 Earnings Call Summary

Canopy Growth reported Q2 2027 results, highlighting a 141% YoY increase in international cannabis revenue and a 44% decline in Storz & Bickel revenue due to economic uncertainty. The company aims for positive adjusted EBITDA in H2 2027, with cultivation improvements expected to boost flower production by 25-30% in early 2028. Canopy also secured EU GMP certification, enabling expansion into European markets beyond dry flower.

$CGCMed

Canopy Growth Q2 Earnings Call Highlights

Canopy Growth reported Q2 revenue growth in Canada and plans to build a dedicated sales force. Storz & Bickel revenue declined 4% but expects a strong Q3. Cultivation improvements aim for 25-30% yield increase. Adjusted gross margin fell to 31% from 33% due to VA reimbursement rate changes. Cash reserves were CAD 320 million as of September 30. The company may pursue a reverse stock split to maintain Nasdaq compliance.